Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Amortization of Deferred Charges (2019 - 2025)

Historic Amortization of Deferred Charges for Wave Life Sciences (WVE) over the last 7 years, with Q3 2025 value amounting to $1.4 million.

  • Wave Life Sciences' Amortization of Deferred Charges rose 1355.37% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 1350.94%. This contributed to the annual value of $4.8 million for FY2024, which is 1333.81% up from last year.
  • As of Q3 2025, Wave Life Sciences' Amortization of Deferred Charges stood at $1.4 million, which was up 1355.37% from $1.3 million recorded in Q2 2025.
  • Wave Life Sciences' Amortization of Deferred Charges' 5-year high stood at $1.4 million during Q3 2025, with a 5-year trough of $512000.0 in Q1 2021.
  • For the 5-year period, Wave Life Sciences' Amortization of Deferred Charges averaged around $992578.9, with its median value being $1.0 million (2023).
  • In the last 5 years, Wave Life Sciences' Amortization of Deferred Charges surged by 7527.27% in 2022 and then soared by 1068.46% in 2023.
  • Over the past 5 years, Wave Life Sciences' Amortization of Deferred Charges (Quarter) stood at $759000.0 in 2021, then increased by 29.51% to $983000.0 in 2022, then grew by 12.0% to $1.1 million in 2023, then grew by 13.44% to $1.2 million in 2024, then rose by 10.01% to $1.4 million in 2025.
  • Its Amortization of Deferred Charges was $1.4 million in Q3 2025, compared to $1.3 million in Q2 2025 and $1.3 million in Q1 2025.